Society is at long last beginning to recognise the potential benefits of psychedelic compounds for improving mental health and wellbeing. One practice in particular that seems to have piqued a great deal of interest is microdosing – the use of small, sub-hallucinogenic doses of psychedelics.
Last year, the Beckley Foundation’s research collaboration with Maastricht University uncovered certain physiological mechanisms that could go some way to explaining the therapeutic potential of this practice. What we need now to better understand its effects, is more research in both healthy and clinical populations.
Amanda Feilding and her team are very excited to be part of the first international, multi-disciplinary research collaboration dedicated to microdosing, alongside Paul Stamets, Pam Kryskow, Zach Walsh and other researchers from the University of British Columbia and Maastricht University, in what will most likely be the largest microdosing study to date.
Powered by Quantified Citizen, a mobile health research platform that is hosting the world’s first mobile microdosing study, we’ll gather knowledge on a wide range of microdosing practices and how they affect mental health, cognitive performance, and more. Additional information can be found on Microdose.me. You can read about their latest study results here.
Nested within this large research project, Amanda Feilding has worked with collaborators in relevant fields, including non-profit organization Psychedelic Data Society, to develop more targeted studies focusing on specific uses of microdosing.
Two of these studies will be open for participation very soon.
“Microdosing could be a great benefit for things like palliative care, to help with inflammation, sleeping, neuroplasticity, pain, overcoming addictions – there’s all sorts of areas where a little mind shift in an upward direction can help the person both psychologically and physiologically.” – Amanda Feilding
Psilocybin for Depression
Type of publication